



# Technical Bulletin

## New Gram-Negative Bacillus Susceptibility Panels

**TO:** Medical Staff and Clients

**FROM:** Dr. Wesley Kim, MD  
Medical Director, DLS and QMC West

Dr. Amy Woron, PhD  
VP & Technical Director  
Microbiology & Molecular

Dr. A. Christian Whelen, PhD  
Scientific Affairs Advisor  
Microbiology & Molecular

Dr. Ana Ortega-Lopez, MD  
Medical Director QMC Punchbowl,  
North Hawaii and Molokai

**DATE:** November 21, 2024

**SUBJECT:** New Gram-Negative Panels offer newer Antimicrobics

Effective December 9, 2024 DLS will be using modernized susceptibility panels for Enterobacterales, *Pseudomonas aeruginosa*, and *Acinetobacter* species. These are designed to present clinicians with more contemporary therapeutic options. The new panels are presented below:

<b>NEW</b> Enterobacterales	<b>NEW</b> <i>Pseudomonas aeruginosa</i>	<b>NEW</b> <i>Acinetobacter</i> species
amikacin	(U) amikacin	(d) amikacin
ampicillin	cefepime	ampicillin/sulbactam
ampicillin/sulbactam	ceftazidime	cefepime
cefazolin	(S) ceftazidime/avibactam	ciprofloxacin
cefepime	(S) ceftolozane/tazobactam	(S) levofloxacin
ceftriaxone	ciprofloxacin	meropenem
ciprofloxacin	(S) levofloxacin	minocycline
ertapenem	meropenem	pip/tazo
gentamicin	pip/tazo	tobramycin
levofloxacin	tobramycin	trimethoprim/sulfa
meropenem		
(U) nitrofurantoin	(S) Suppressed from routine reporting	
pip/tazo	(U) For urinary tract infections only	
trimethoprim/sulfa	(d) Not reported for <i>Acineto baumannii</i> complex	

Please refer any questions to Tori Enomoto, Manager - DLS Microbiology Lab at 808-441-5470, or DLS Client Services at 808-589-5101.